Humana Inc. $HUM Shares Sold by T. Rowe Price Investment Management Inc.

Key Points

• T. Rowe Price Investment Management Inc. has significantly reduced its holdings in Humana Inc. by 89.6%, selling 1,438,201 shares and now owning 167,570 shares worth approximately $44.34 million.
• Several institutional investors, including Deutsche Bank AG and Envestnet Asset Management Inc., have recently adjusted their stakes in Humana, with hedge funds holding 92.38% of the stock.
• Humana's recent earnings report showed a missed EPS estimate by $0.05, and the company announced a quarterly dividend of $0.885 per share with a 1.2% annual yield.

T. Rowe Price Investment Management Inc. lessened its holdings in Humana Inc. (NYSE:HUM - Free Report) by 89.6% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 167,570 shares of the insurance provider's stock after selling 1,438,201 shares during the period. T. Rowe Price Investment Management Inc. owned about 0.14% of Humana worth $44,340,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Cary Street Partners Investment Advisory LLC raised its stake in shares of Humana by 63.9% in the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock worth $31,000 after buying an additional 46 shares during the period. Riverview Trust Co bought a new position in shares of Humana during the 1st quarter valued at approximately $34,000. Garde Capital Inc. purchased a new stake in shares of Humana in the first quarter worth approximately $36,000. Zions Bancorporation National Association UT purchased a new position in shares of Humana during the first quarter worth approximately $37,000. Finally, Whipplewood Advisors LLC increased its position in Humana by 639.1% during the 1st quarter. Whipplewood Advisors LLC now owns 170 shares of the insurance provider's stock valued at $45,000 after purchasing an additional 147 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Stock Performance

NYSE HUM traded up $0.73 on Thursday, reaching $297.99. The stock had a trading volume of 662,796 shares, compared to its average volume of 1,705,884. The stock has a market cap of $35.84 billion, a P/E ratio of 22.89, a price-to-earnings-growth ratio of 1.76 and a beta of 0.44. Humana Inc. has a 12-month low of $206.87 and a 12-month high of $382.72. The business's 50-day moving average price is $252.05 and its 200 day moving average price is $254.08. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing the consensus estimate of $6.32 by ($0.05). The company had revenue of $32.39 billion for the quarter, compared to analysts' expectations of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%.Humana's revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter last year, the company earned $6.96 EPS. Humana has set its FY 2025 guidance at 17.000- EPS. As a group, equities analysts expect that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a $0.885 dividend. The ex-dividend date is Friday, September 26th. This represents a $3.54 annualized dividend and a dividend yield of 1.2%. Humana's dividend payout ratio is currently 27.17%.

Analyst Upgrades and Downgrades

Several analysts have recently commented on HUM shares. Bank of America decreased their price objective on Humana from $320.00 to $260.00 and set a "neutral" rating for the company in a report on Tuesday, June 17th. Wells Fargo & Company cut their price objective on Humana from $348.00 to $344.00 and set an "overweight" rating on the stock in a report on Thursday, August 14th. Raymond James Financial upgraded shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price target on the stock in a research report on Thursday, May 1st. Truist Financial decreased their price objective on shares of Humana from $280.00 to $260.00 and set a "hold" rating on the stock in a report on Wednesday, July 16th. Finally, Cantor Fitzgerald restated a "neutral" rating and set a $290.00 target price on shares of Humana in a report on Thursday, May 1st. Seven analysts have rated the stock with a Buy rating and sixteen have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $283.29.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.